Secondary prevention in CAD: A significant correlation between LDL-cholesterol (LDL-C) achieved therapeutically and extent of progression reduction claims for LDL-C target levels < 100 mg/dl  by Bestehom, H.P. et al.
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11:00 
~ Moduletlen of  Smooth Muscle Cell 
MigretloNInvasion by Plasmln_ogen.Ac:,f~ltors, . 
Urok inue  Receptor, end Low gensny Ltpoprotem 
Receptor Related Protein 
Shunichire S. Okeda, Stephen R. Grobmyer, Elliot S. Barnethan. Univers[ly 
of pennsytvania, Philadelphia, PA 
Smooth muscle cell (SMC) migration is an early response to vascular in. 
jury contdb~n~ to the development of intimal thickening. Upregulation of 
several component£ of the plasminegan activator (PA) system have been 
documented after vascular injunJ. We utilized a Transwell tilter assay system 
and cultured human umbilical vein SMC to more thoroughly define the role of 
four different components of the PA system on SMC migmbsn: 1) plasmino- 
gen activafors, 2) plasmin, 3) PA receptors (e,g, u-PAR) and 4) PA clearance 
receptors (e.g. low density lipoprotein receptor elated protein, LRP). Active 
two chain urokinase stimulated random migration (1.9:1:3 fold increase, 
0.36 nM, p = 0.0001) which was inhibitsble by diisopropytiluorephosphate 
(DFP). plasmlnogen activator Inhibitor-1 (PAl-l) or apretinin. The aminater- 
minel fragment of u-PA (ATF) increased migration as well (1.4 :E 0.1 fold, p < 
0.001) but was net ichgoitable by apretinin. Low molecular weight u-PA also 
enhanced migration (1.5 • 0,3 told, p = 0.003); the effe~ was inhibltable by 
apretinin and was additive when combined with ATF. The stimulatory effect 
was not specific for u-PA in that t-PA also stimulated migration (1.7 :t: 0.1 
fold, 10 nM, p = 0.0001 ); the augmentation was inhibitsble by DFP, PAl-l, or 
apmtinin and was additive to the u-PA effect (2.4 • 0A fold, p < 0.02 vs. t-PA 
alone). Antibodies to either u.PAR or LRP inhibited migration (19 ± 9% and 
43 ± 4% of control, respectively, p = 0.0001) but only anti-u-PAR antibodies 
inhibited baseline SMC invasion (41 :l: 9% of control, p = 0.01 ) in a collagen 
gel assay. These data demonstrate the ability of several components of the 
PA system to modulate SMC migration and invasion in vifre via pfasmin 
dependent and independent mechanisms. 
11:15 
~75~--~ Efficient Perivascular Gene Adenovirus-Mediated 
Transfer and Protein DelP,-ery by e Transvaecular 
Injection Catheter 
Khawar Mehdi, Robert L Wilensky, Sang Hong Baek, Bruce C. Trapnsll, 
Keith L March. Krannert Institute of Cardiol~, Indiana University Medical 
Center, Indianapolis, IN; RL Roudebush VAMC, Indianapolis, IN; Genetic 
Therapy, Ir, corporated, Gaithersburg, MD 
Intralumlnsl delivery catheters have successfully delivered agents to vascu- 
lar tissue in vivo, but are characterized by limited efficiency, partially due to 
intxavascelar loss of agent. The kinetics of adanoviral sell attachment also 
dictate the need for prolonged vector exposure times to optimize transduc- 
tion. The use of needle-tipped il~.; ,%'tion catheters (NIC) capable of direct 
perivascular injection of agents may enhance delivery efficiency as well as 
transduction by intet3titial deposition of agent without he need for prolonged 
vascular occlusion. The delivery dis~'bution, efficiency and transduction prop- 
erties of NIC were evaluated in vivo in 18 normal porcine coronary artedee 
acutely following injection of 12Sl-elbumin or fiuorescein-conjugated hupadn; 
and 7 days after injection of a replication-deficient recombinant edenovirai 
vector encoding nuclear-targeted p-gelastosklase (~-gal) as a marker gene. 
The fractional delivery of albumin was 0.54 4- 0.3(P,o into the artedel wall, 
0.98 -t- 0.70% into the perivascular space, and 2.7 ~ 2.4% into podvascu- 
lar myocardium; while evaluation of the entire myocardium surrounding the 
target vessel confirmed presence of 15% of the total agent delivered. Ruo- 
reeceinaled hepedn was predominantly seen in the adventifia nd perivss- 
cular tissue, and was disth'buted longitudinally for distances of 15-20 ram. 
Adanovirai gone transfer was seen with high frequency in advantitia and 
perivascular tissues extending up to 10 mm from the target vessel, as well as 
in the epicardium overlying the delivery sites, suggesting convective vector 
transport; but medial transduction was limited. Cathetsr-based transvascalar 
injection provides for cumparatively elficlent agent delivery, and may repre- 
sent an approach to the genatio modulation of a range of perivescular tissues 
without he need for prolonged vascular occlusion. 
11:30 
~ Hepadn Reverses the Antipla;el¢~ Effect o f  N~ie  
Oxide 
Gilbert R. Upehurch, Jr., Jane E. Freedman, Yingyi Zhang, George 
N. Welch, Joseph Loscalzo. Brigham and Women's Hospital, Boston,/VIA; 
Boston Universfty School of Medicine, Boston, MA 
Hepadn has been shown to increase thromboxane .% generation by platelats 
in vivo, and we have shown that expression of the plalaiet activation antigen 
P-solectin is induced by hepadn. The mechanism for these adverse, pro- 
thrombotic effects of hopadn remains unknown. Since endothelium-dedved 
nit'do oxide (NO) is a potent inhibitor of platalat activation, we examined 
the effects of hepadn on the antlplatelat effects of this endothelial product. 
Increasing concentrations of hepadn (0, 0.5. 5. or 50 Ulmt) were incubated 
with gel-filtered platelets to which the NO-donor S-nitroso-glutathione was 
added and platelet aggregation responses to adenosine 5'-diphosphate de- 
termined. While Incubation of plateleto with hapadn alone did not alter the 
aggrsgafio, response and incubation with 1 p,M S-nitroso-glutathtone inhib- 
ited the normalized extent of aggregation by 50%, the addition of hepafln 
to S-nifreso-gfutalhione l d to a dose-dependent increase in aggregation 
response (ECso = 1 39 U/ml, p ,= 0.03 by ANOVA). Using the Gdess reaction 
and the abaorbance of the chmmophore of acidified nitrite, we observed a 
concomitant dose-dependent decrease in NO with increasing hepadn con- 
contmtions (IOso = 7.30 U/ml, p = 0.007 by ANOVA). The Increase In ag- 
gregation response correlated negatively with the decrease in nitrite in these 
experiments (R - -0.74). These data show that hepadn can impair the an- 
tiplataiet effects of nitric oxide and suggest that one mechanism by which 
hepadn promotes platelat activation in vivo is by attenuating the inhibitory 
effects of endothelium-dedved nitric OXide. 
11:45 
~ ' ~  Duel Inhibition of  Neutral Endopeptidaee (NEP) end 
Angiotensin Converting Enzyme (ACE) Suppresses 
Atherogeneeis and Improves Endothelial Function 
In Hypercholeeteretemlc Rabbits 
Iffikhar J. Kutlo, Vtrgiola M. Miller, George M. Lawson, John C. Bumott Jr.. 
Mayo Clini~ Rochester, MN 
NEP and ACE am coiocalized ectoenzymes which metabolize several va- 
soactive peptides. Combined inhibition of the two enzymes could have unique 
antiatharogentc effects by augmenting the anfimitogenic-vasorelaxing prop- 
erties of the natriuretio peptidas and kinlns whilst decreasing levels of angio- 
tensin II. We investigated the effects of UK-81262 (UK) (Pfizer), a dual 
inh~itor of NEP and ACE, on vascular reactivity and atherogenests In male 
New Zealand White rabbits fed a 1% cholesterol diet for 10 weeks. Animals 
wsm either untreated (n = 6), or treated with UK 5 mg/kg/day orally (n = 8). 
At 10 weeks, mean arterial blood pressure (86 ± 4 vs 81 4- 3 mmHg) and 
plasma cholestarel evels (1937 -4-195 vs 2022 ~: 162 mg/di) were compara- 
ble in the two groups. The percent surface area of the proximal thoracic aorta 
affected by athemma (measured after Oil-Red O staining) was significantly 
lower in the treated group (22 ~ 7=/0 vs 48 + 9%; p < 0.01). Endothelial 
dependent relaxations to acetylcheline, in vascular dngs from the thoracic 
aorta, were signifcantly greater in the UK treated group compared to the 
untreated group: 
MR ECS0 
Untreated 56 ~: 6. 6.4 ~ 0.34 
Treated 864. p_6*,(p < 0.001 ) 7.0 ± 0.03"(p < 0.02) 
MR = maximum relaxation. EC50 - concentretion causing a 50% decrease of 
phanylphflne induced contraction and expressed as a negative logarithm of the mo, 
lar concenlratton. 
These results demonstrate that chronic dual inhibition of ACE and NEP 
suppresses atherogenesis and improves endothelial function in hypercholes- 
terolemio states in the absence of any significant effects on blood pressure 
or plasma cholesterol. 
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~ ' - ]  Secondary Prevention in CAD: A Slgnmcant 
Correlation Between LOL-Cholesterol (LDL-C) 
Achieved Therapeutically and Extent of  Progression 
Reouctlon Clmms TOr LOL-C Target Levels < 100 
mg/dl 
H.P. Bestehom, U.F.E. Rensing, H. Roskamm, L. Benesch, G. BlOmchen, 
P. Mathes, L Kuppenbarger. HerzoZentrum Bad Krozingen; Fachklinik 
Rhein Ruhr Essen; lOin. Roderbirken Leichlingen; Klinik H6heorisd; CHUV 
Lausanne 
The Coronary Intervention Study (CIS) is a multicenter, andomized, double- 
blind, placel0o-controlled study to investigate the effect of lipid-lowering with 
simvastatin (S) on progression of coronary artery disease (CAD) in 254 men 
with documented CAD and hypercholesterelemia. Treatment with up to 40 
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mg S or placebo (P) included iet and was persued for 2.3 years. In the P- 
group, serum lipide remained unchon0ed, while the S-group showed a 35*/0 
LDL-C decrease. 20510ts (81%) had a 2 r~ coronary angiography and 203 
(80%) were evalusble by QCA. In the ,S-Group, corunary progression (per 
patient mean change in minimum lumen diameter (t~minD) was significantly 
less than in the P-Group (-0,02 mm vs -0.1 ram; p = 0.0022). 
In the S group (n = 103), the individual absolute LDL-C-levels achieved 
therapeutically were slgnlfcantly correlated with the correspaoding MLD 
decreases (R = 0.241; g < 0.015). Dividing the correlated parametem in 
tertilea of their distribution curves, "pmgrassion" (mean MLD-lass of > +0.04 
ram) o¢cured in 45.4% in the upper (>_ 115 mg/di), in 34.4o/o in the medium 
(95-114 mg/dl) and in 23.5*/= in the lowest LDL-C-ledile (_< 54 mg/dl). The 
corresponding rates for "No Change, Regression'(mean MLD-ICSs < +0.04 
mm) were 54.6°/0, 08.6% and 76.5*/0. 
Conclusion: In patients with elevated LDL-C-levels, CAD-progreesion can 
be slowed down significantly by lipid lowering with S. The extent ef pro- 
greseion reduction is correlated with the absolute LDL-C-leveis achieved 
therapeutically; based on the tedile-dependent progression rates, LDL-C 
target levels should be below 100 mg/dl. 
1 0:45 
~ '5"~ Scandinavian Simvaststm Study (4S): Survival 
Cost-Effectiveness (CE) of Cholesterol Lowering 
Treatment 
Brace Kinoslan, Henry Glick, J Sanford Schwartz for the 4S Group. 
University of Pennsylvania, Philadelphia, PA 
In contrast to the demonstrated clinica~ benefits of cholesteml-mod@ing 
drugs in lOtS with CAD and moderate cholesterol elevation, less evidence is 
available about CE. We assessed the CE of eimvastatin Rx usin~ a simulation 
model integrating data from 4S. 
Life expectancies were estimated from 4S survival using Weibull failure 
time models. Cardiovascular hospitalization and drug use were derived from 
,IS data. Cost and benefds were discounted 5"/0 per yr. Medical service costs 
were estimated using adjusted Medicare DRG & RBRV8 reimbursement 
(lower bound) and Medstet allowed charges (upper bound); drug costs were 
estimated using average wholesale price plus dispensing fees. CE analyses 
were performed for both the 5 yr 4S observation period and projected for 
lifetime Rx. 
During the 4S follow-up, treated pat]ants lived an additional 0.065 ym 
(Discounted: 0.053 yrs [95% Ch 0.019-0.087]). Simvastatin cost was part~ally 
offset by reduced medical care expenditures. Net costs of Rx were $808 
(Medstat) - $3,526 (Medicare) over the 5 yr ,IS observation period. Projected 
incremental survival for lifetime Rx was 2.22 yrs (Discounted: 0.926 yrs [95% 
CI: 0.561-1.29]). Expected net Rx cost was $6,798 (Medstet) - $11,045 
(Medicare), with coet/YOLS of $7,340-$11,927 [95*/,, Ch $5,918-$44,517]. 
While the CE of simvastatin Rx in pts with CAD and moderate cholesterol 
intervention is within the range of accepted medical interventions when the 
analysis is restricted to the 5-year 4S observation period, long-term Rx is 
even more costoeffective, asthe greatest benefds occur after the initial 5 yrs. 
11:00 
[ ' -~ '~ Atheroeclero$1s Plaque Regression on the Thoracic 
Aorta Assessed by Transe~ophegeal 
Echocardlegraphy in Patients With Oyspllpidemla 
and Coronery Artery Dleease 
Miguel Zabaigoitia, William Linn, Rosario Mercado, Lori Oneschuk, 
Kamn Vanden~oud, Sheri Y. Noftestad, John Come,° Robert A. O'Rourke. 
University of Texas HIth Science Ctr, San Antonio, TX 
Transesophageal echocardiography (TEE) provides an excellent means to 
characterize athemsdemtic plaques (AP) on ascending (AA), transverse 
{TA), and descending aorta (DA). To determine if TEE can be used to evaluate 
AP modification, 10 male pts (mean age 63 yrs) with dyslipldemia nd 
documented coronary artery disease were treated eccording to National 
Chefestoml Education Program. AP areas were planimetered at 2 cm apart 
along the AA, TA, and DA from biplane TEE at baseline and at 12 moneys 
of therapy. Exact distance from the incisors was indicated to assure that 
comparisons on the same patient were taken at the same site. Total plaque 
area (TPA) index was calculated by adding all areas suitable for cempadson 
and divided by the number of entries. Results: When TPA index at 12 months 
was compared to baseline, it changed from 1.54 cm ~ to 1.15 cn~, p < 
0.01, a 25*/0 reduction; total cholesterol changed from 209 mg/di to 170 
mg/di, p < 0.001, a 19% reduction, low density llpupmtaio (LDL-cholasterol) 
changed from 140 mg/di to 109 mg/dl, p < 0.002, a 22% reduction; and total 
cholesterol/high density lipaprotein ratio changed from 5.6 to 4.8, p < 0.08, 
a 14% reduction. TPA index and LDL-cholasterol reductions correlated well 
r = 0.76, SEE = 0.19, p < 0.05. Conc/us/on: Agrassive lipid lowering therapy 
results in a 25=/, reduction on AP of the thoracic aorta after 12 months. 
Reduction of LDL-cholesterol correlates well with AP regression. TEE is a 
useful non-invasive technique to evaluate AP moo~tication by lipid lowering 
treatment. 
11:15 
[ -7~- ' ]  RegmsMon of Atheroma Seen With intravascular 
Ultrasound: A Placebo Controlled Study of the 
Effect of Gemfibrozil on Peripheral Atherosclerosis 
Andrew N. Deaner, Jeff Ball, Arzu A. Cubskco, Simon Meg~y, Peter 
J. Scott, Paul Brooksby, Mohen Lal, Mchan Sivanathan, Gordon J. Witlir, ms. 
Killingbeck Hospital, Leeds, UK 
The Killingbac~ Regression of Atheroma Study (KRAS) was a double blind 
placebo ~ntmlled study of the effect of gemfibrez, plus I'~oid lowering diet 
remus lipid lowering diet only on atheroma in the distal aorta and lliao ar- 
teries of patients with coronary artery d '~sa  and modemt~ raised liplds 
(mean total cholesterol = 6.8 retool/I). Serial cress-sectional images of these 
vessels were recorded at 2 mm intervals using a 6 French, 20 MHz intravas- 
cuter ultrasound (IVUS) catheter during a controlled pull back in 39 patients 
(male 26, ages 38-70). Patients were given dietary advice and randomized 
to treatment with ge~l  600 log bd or placetlo. After a mean of 371 
days the 31 patients (17 in gemf'(mo:,q group) who completed the study 
undenvent repeat IVU$ imaging. A total of 1144 segments of artery were 
matched accord~g to ~ position oi bifiacaffon paints and measurements of 
cress-sectional rea of atherema made by compete~ed planimeW. Base- 
line demographics, phystcsI end lipid data were well matched between the 
bealment groups. In the gerrvF'mmzfl group signif'¢arrt eductions compared 
to the diet only group, were seen in total cholesterol (9%, p = 0.03), triglyCo 
endas (55%, p = 0.0001) and LDtJI-IDL ratio (26./o, p = 0.62), a signtf'¢ant 
increase in HDL cholesterol level (27°/= p = 0.05) was also seen. No overall 
significant change in the mean o'nss-sectiorml area of efherema was se~.n 
in the d'vet only greup but them v,'es an g.85% decrease of this n'masumme-vt 
in the gemflbrozil group (p = 0.009). Analysis of cruse-sectional plaque aP.~ 
changes within individual patients howed significant (p < 0.05) ~;on  
of > 5% ef plaque in 5 of the ~ ' 1  greup but only 1 of the o-ret only 
group. 
Thus, this study using repeated IVUS measurements of plaque crcss- 
sectional area showed significant r~-~r~ion of peripheral etheroma in pa- 
tients treated with gemlromzil plus I~id lowering diet. 
11:30 
[7 -~- ]  Pravaststin Reduces Transient Myocardial Ischemla 
in Patients With Angina Pectoris and Significant 
GAD 
Ad J van Boven, J Wouter Juk.,mla, Am'lko H Zwinderman, Albert 
VG Bnnchke, Kong I Lie for the REGRESS Study. The In tenm/~ 
Institute, ICIN, Utmch~ Thoraxcent~, Univ. Hospital, Groningen. 
The Nethe4anOs 
Usual anti-anginal Imetment, including PTCA and CABG, will relieve symp- 
toms, but a cemplete abolishment of Transient Myocardial Ischemla (TMI) is 
not always aCained. We hypathes~.ed that pravastatin 40 mg (P) in add~ion 
to conven~onal theral~ may reduce TMI end studied its 2 year ~ 
effect in 768 patients from the REGRESS study, using 48 horn ambulatory 
ECG's. In this placebo con~relled stody only men wifh angina puctods, doc- 
umented coronanj ariew dtsease and a cholesterol bo{ween 4 and 8 mmol/I 
were incloded. Separate randO~T&~ blocks ware made from pls who un- 
~ respec~ PTCA, CABG onnedical menagement. Ouring Honer 
monitoring antHschan~ medica~ was continued. To analyze the ~ect 
of P we used a logistic re@-~ medel wt~ random effects. Dudng the 
study the parceetage of patients with TMI ~ frem 28% to 19% with 
P and increased from 19% to 23% with placebo. The odde ratio for TMI of 
P versus placebo was 0.62 (95% Cl 0.41-0.93; p = 0.621). Total duration 
of ischem~ and ischcnnic burden were reduced with 38 n~'l and 19 mm.min 
with P and 9 rain aod 8 mm.ndn with placebo, p = 0.017 and 0.0088 respac- 
tively. P reduced TMI d,~,~'ta optimal anti-anginal lmatment. These data on 
the anti-ischendc action of P are in rme with ils reduction in clinical events in 
REGRESS. 
11:45 
~ Lowering "Desirable" Levels Cholesterol ~n~proves 
Flow-Mediated Vasoactivity in Healthy, Middle-Aged 
Men 
Robert A. Vogel, M~rv C. Cormtti, Ga~ D. Plothick. University of Maryland 
School of Med'~ne, B "~=mora, MD 
Cunent Na~nal Cholesterol Educe, on Program g~errnes consider desir- 
